Edwards Lifesciences Co. (NYSE:EW) Shares Purchased by Cwm LLC

Cwm LLC grew its holdings in shares of Edwards Lifesciences Co. (NYSE:EWFree Report) by 45.9% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 25,519 shares of the medical research company’s stock after purchasing an additional 8,026 shares during the period. Cwm LLC’s holdings in Edwards Lifesciences were worth $2,439,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. DSM Capital Partners LLC bought a new position in shares of Edwards Lifesciences during the fourth quarter worth about $28,000. Turtle Creek Wealth Advisors LLC bought a new position in Edwards Lifesciences in the 4th quarter worth about $34,000. Pingora Partners LLC acquired a new stake in shares of Edwards Lifesciences in the fourth quarter valued at approximately $38,000. Operose Advisors LLC raised its holdings in shares of Edwards Lifesciences by 247.0% during the third quarter. Operose Advisors LLC now owns 635 shares of the medical research company’s stock valued at $44,000 after buying an additional 452 shares during the last quarter. Finally, SRS Capital Advisors Inc. boosted its position in shares of Edwards Lifesciences by 292.6% during the third quarter. SRS Capital Advisors Inc. now owns 636 shares of the medical research company’s stock worth $44,000 after buying an additional 474 shares during the period. Institutional investors own 79.46% of the company’s stock.

Insider Activity

In other news, CEO Bernard J. Zovighian bought 580 shares of the firm’s stock in a transaction that occurred on Monday, May 6th. The stock was acquired at an average cost of $85.74 per share, with a total value of $49,729.20. Following the completion of the purchase, the chief executive officer now owns 3,268 shares of the company’s stock, valued at $280,198.32. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other Edwards Lifesciences news, VP Daniel J. Lippis sold 857 shares of the firm’s stock in a transaction on Tuesday, May 7th. The stock was sold at an average price of $85.60, for a total transaction of $73,359.20. Following the completion of the sale, the vice president now owns 23,890 shares of the company’s stock, valued at approximately $2,044,984. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Bernard J. Zovighian acquired 580 shares of the company’s stock in a transaction dated Monday, May 6th. The stock was bought at an average cost of $85.74 per share, for a total transaction of $49,729.20. Following the completion of the transaction, the chief executive officer now directly owns 3,268 shares of the company’s stock, valued at $280,198.32. The disclosure for this purchase can be found here. Insiders sold 127,104 shares of company stock worth $11,267,464 in the last quarter. Corporate insiders own 1.27% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on EW. Oppenheimer raised their price target on Edwards Lifesciences from $93.00 to $100.00 and gave the company an “outperform” rating in a report on Monday, March 18th. Evercore ISI reduced their price objective on shares of Edwards Lifesciences from $92.00 to $89.00 and set an “in-line” rating for the company in a research report on Friday, April 26th. Deutsche Bank Aktiengesellschaft upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating and lifted their target price for the stock from $86.00 to $103.00 in a report on Tuesday, May 14th. StockNews.com downgraded shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Tuesday. Finally, Piper Sandler upped their price target on shares of Edwards Lifesciences from $85.00 to $88.00 and gave the company a “neutral” rating in a research report on Friday, April 26th. One analyst has rated the stock with a sell rating, six have issued a hold rating and fourteen have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $95.06.

Read Our Latest Analysis on EW

Edwards Lifesciences Trading Up 1.9 %

Shares of EW traded up $1.65 during trading hours on Wednesday, reaching $88.52. The stock had a trading volume of 3,709,988 shares, compared to its average volume of 2,165,861. Edwards Lifesciences Co. has a 52 week low of $60.57 and a 52 week high of $96.12. The firm has a 50-day moving average of $87.56 and a 200 day moving average of $84.22. The company has a market cap of $53.34 billion, a P/E ratio of 38.16, a P/E/G ratio of 3.18 and a beta of 1.11. The company has a quick ratio of 2.67, a current ratio of 3.75 and a debt-to-equity ratio of 0.08.

Edwards Lifesciences (NYSE:EWGet Free Report) last released its earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.02. The firm had revenue of $1.60 billion during the quarter, compared to analysts’ expectations of $1.58 billion. Edwards Lifesciences had a return on equity of 22.86% and a net margin of 23.01%. On average, sell-side analysts expect that Edwards Lifesciences Co. will post 2.77 earnings per share for the current fiscal year.

About Edwards Lifesciences

(Free Report)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Featured Articles

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Co. (NYSE:EWFree Report).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.